POLO: A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2mutation (gBRCAm) who have not progressed following first-line chemotherapy.

Abstract

TPS4149 Background: Germline mutations in BRCA1/2 define a molecular subgroup of PC that in some populations has a prevalence as high as 15%. gBRCAm-defective tumors are intrinsically sensitive to ...